Jeryl Hilleman Net Worth

The estimated Net Worth of Jeryl L Hilleman is at least $2.63 Million dollars as of 15 June 2023. Ms. Hilleman owns over 4,162 units of NovoCure Ltd stock worth over $264,463 and over the last 14 years she sold NVCR stock worth over $1,946,610. In addition, she makes $414,303 as Independent Director at NovoCure Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Hilleman NVCR stock SEC Form 4 insiders trading

Jeryl has made over 24 trades of the NovoCure Ltd stock since 2011, according to the Form 4 filled with the SEC. Most recently she sold 4,162 units of NVCR stock worth $118,076 on 15 June 2023.

The largest trade she's ever made was exercising 51,200 units of NovoCure Ltd stock on 1 April 2019 worth over $764,416. On average, Jeryl trades about 5,449 units every 82 days since 2010. As of 15 June 2023 she still owns at least 15,349 units of NovoCure Ltd stock.

You can see the complete history of Ms. Hilleman stock trades at the bottom of the page.

Jeryl Hilleman biography

Jeryl Hilleman serves as Independent Director of the Company. Ms. Hilleman recently retired from Intersect ENT, Inc., a healthcare equipment company, where she served as chief financial officer from 2014 to 2019. Prior to joining Intersect ENT, Ms. Hilleman was chief financial officer and secretary of Ocera Therapeutics, Inc. from 2013 to 2014. Ms. Hilleman also served as chief financial officer of Amyris, Inc., from 2008 to 2012, and as chief financial officer of Symyx Technologies, Inc. from 1997 to 2007. She has been Director of Minerva Neurosciences, Inc. since 2018 and director of SI-Bone, Inc. since 2019. From 2005, Ms. Hilleman served as a director of Xenoport, Inc., a biopharmaceutical company, until it was acquired in 2016. She holds A.B. in History, Brown University; M.B.A., Wharton Graduate School of Business.

What is the salary of Jeryl Hilleman?

As the Independent Director of NovoCure Ltd, the total compensation of Jeryl Hilleman at NovoCure Ltd is $414,303. There are 12 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.

How old is Jeryl Hilleman?

Jeryl Hilleman is 62, she's been the Independent Director of NovoCure Ltd since 2018. There are 5 older and 17 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.

What's Jeryl Hilleman's mailing address?

Jeryl's mailing address filed with the SEC is C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE, CA, 94005.

Insiders trading at NovoCure Ltd

Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.

What does NovoCure Ltd do?

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Complete history of Ms. Hilleman stock trades at Amyris Inc, Cutera Inc, Intersect ENT Inc, Minerva Neurosciences Inc, NovoCure Ltd, and SI-BONE Inc

NovoCure Ltd executives and stock owners

NovoCure Ltd executives and other stock owners filed with the SEC include:

• William Doyle,
  Executive Chairman of the Board
• Asaf Danziger,
  President, Chief Executive Officer, Director
• Michael Ambrogi,
  Vice President - Senior Technology Fellow
• Wilhelmus Groenhuysen,
  Chief Operating Officer
• Pritesh Shah,
  Chief Commercial Officer
• Asaf Danziger,
  Pres, CEO & Director
• William F. Doyle,
  Exec. Chairman
• Wilhelmus C. M. Groenhuysen,
  Chief Operating Officer
• Todd C. Longsworth,
  Gen. Counsel
• Ashley Cordova,
  CFO & VP of Investor Relations
• Pritesh Shah,
  Chief Commercial Officer
• William Vernon,
  Lead Independent Director
• Jeryl Hilleman,
  Independent Director
• Martin Madden,
  Independent Director
• Sherilyn McCoy,
  Independent Director
• David Hung,
  Independent Director
• Kinyip Gabriel Leung,
  Independent Director
• Frank Leonard,
  Chief Development Officer
• Todd Longsworth,
  General Counsel
• Ely Benaim,
  Chief Medical Officer
• Ashley Cordova,
  Chief Financial Officer
• Dr. Ely Benaim M.D.,
  Chief Medical Officer
• Barak Ben Arye,
  Gen. Counsel
• Ingrid Goldberg,
  VP of Investor Relations
• Prof. Yoram Palti M.D., Ph.D.,
  Founder & CTO
• Uri Weinberg M.D., Ph.D.,
  Chief Science Officer
• Dr. Ely Benaim,
  Chief Medical Officer
• William Patrick Burke,
  Chief HR Officer
• Prof. Yoram Palti,
  Founder & CTO
• Timothy J Scannell,
  
• Eilon D. Kirson,
  Chief Scientific Officer
• Gert L.Volati Ltd Perlhagen,
  
• Peter M. Melnyk,
  Chief Commercial Officer
• Yoram Palti,
  Chief Technology Officer
• Charles G Iii Phillips,
  Director
• Louis J Jr Lavigne,
  Director
• Ltd Volati,
  10% owner
• William Fwfd Ventures Fund ...,
  
• Gert L. Perlhagen,
  Director
• William T. Burkoth,
  Director
• Capital Vii, L.P.Pomona Cap...,
  
• Moshe Giladi,
  Chief Science Officer
• Nicolas Leupin,
  Chief Medical Officer
• Robert J Jr Mylod,
  Director
• Timothy J. Langloss,
  Director
• Hansjoerg Wyss,
  10% owner
• Allyson J Ocean,
  
• William Patrick Burke,
  Chief Human Resources Officer
• Uri Weinberg,
  Chief Innovation Officer
• W Anthony Vernon,
  
• Kristin Stafford,
  
• Gabriel Leung,
  
• Arye Barak Ben,
  General Counsel
• Michal Nath Puri,
  Chief Human Resources Officer